Advertisement

Drugs

, Volume 58, Issue 2, pp 305–311 | Cite as

Palivizumab

  • Lesley J. ScottEmail author
  • Harriet M. Lamb
Adis New Drug Profile

Abstract

  • ▴ The humanised monoclonal antibody palivizumab has been developed for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants at high risk; RSV is the most common cause of lower respiratory tract infections in infants.

  • ▴ Palivizumab specifically inhibits an epitope at the A antigenic site of the F protein of RSV subtypes A and B. RSV replication was inhibited in nasal and tracheal aspirates from infants receiving palivizumab 15 mg/kg.

  • ▴ Mean 30-day trough serum concentrations of palivizumab were consistently about 70 mg/L in infants receiving repeated intramuscular or intravenous palivizumab 15 mg/kg. This is above the target serum concentration of 40 mg/L estimated to reduce pulmonary RSV replication by >99% in animal studies.

  • ▴ In a large multicentre trial in 1502 infants at high risk of RSV infection, intramuscular palivizumab 15 mg/kg more than halved the incidence of RSV-attributable hospitalisation to 4.8% compared with 10.6% in placebo recipients.

  • ▴ In the same group of high-risk infants, palivizumab significantly decreased total days in hospital attributable to RSV infection, days with increased supplemental oxygen requirement, days with moderate to severe lower respiratory tract infections and the incidence of admissions to intensive care. It had no effect on the incidence or total number of days of ventilation.

  • ▴ Palivizumab was well tolerated during clinical trials in infants at risk of RSV infection. The incidence of adverse events was similar in placebo (10%) and palivizumab (11%) groups. Fever, irritability and injection site reaction were the most commonly reported adverse events.

Keywords

Adis International Limited Respiratory Syncytial Virus Respiratory Syncytial Virus Infection Haematopoietic Stem Cell Transplantation Palivizumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Groothuis JR. The role of RSV neutralizing antibodies in the treatment and prevention of respiratory syncytial virus infection in high-risk children. Antiviral Res 1994; 23: 1–10PubMedCrossRefGoogle Scholar
  2. 2.
    Hall CB, McCarthy CA. Respiratory Syncytial Virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious disease. 4th ed. v. 2. New York: Churchill Livingstone Inc., 1995: 1501–19Google Scholar
  3. 3.
    Wyde PR. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res 1998; 39: 63–79PubMedCrossRefGoogle Scholar
  4. 4.
    Weltzin R. The therapeutic potential of monoclonal antibodies against respiratory syncytial virus. Expert Opin Invest Drug 1998; 7(8): 1271–83CrossRefGoogle Scholar
  5. 5.
    Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanised respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial viras in high risk infants: a consensus opinion. Pediatrics 1999; 18: 223–31Google Scholar
  6. 6.
    Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997 Nov; 176: 1215–24PubMedCrossRefGoogle Scholar
  7. 7.
    Branco L, Barren P, Gross R, et al. Development of a broadly reactive humanised monoclonal antibody (Mab) for the prevention of severe lower respiratory tract disease caused by respiratory syncytial virus [abstract no.P-57]. In: 17th Annual Meeting of European Society for Pediatric Infectious Diseases.:, 1999Google Scholar
  8. 8.
    Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998 Dec; 178: 1555–61PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson S, Griego SD, Pfarr DS, et al. A direct comparison of the activities of two humanized respiratory syncytial viras monoclonal antibodies: MEDI-493 and RSHZ19. J Infect Dis 1999; 180: 35–40PubMedCrossRefGoogle Scholar
  10. 10.
    Piedimonte G, King KA, Holmgren NL, et al. Humanised monoclonal antibody against respiratory syncytial virus (palivizumab) prevents RSV-induced neurogenic inflammation in rat airways [abstract no. 2089]. In: Annual Meeting of the Pediatric Academic Societies; 1999 May 1–4, San FranciscoGoogle Scholar
  11. 11.
    Sáez-Llorens X, Castafio E, Null D. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 1998 Sep; 17: 787–91PubMedCrossRefGoogle Scholar
  12. 12.
    IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998 Sep; 102 (Part 1): 531–7CrossRefGoogle Scholar
  13. 13.
    Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998 Feb; 17: 110–5PubMedCrossRefGoogle Scholar
  14. 14.
    Boeckh M, Bowden RA, Berrey MM, et al. Phase I evaluation of a RSV-specific humanized monoclonal antibody (MEDI-493) after haematopoietic stem cell transplantation [abstract]. 38th International Conference on Antimicrobial Agents and Chemotherapy 1998 Sep 24; 604: 593Google Scholar
  15. 15.
    Null DM, Connor EM, Palivizumab Study Group. Evaluation of immunogenicity and safety in childen receiving palivizumab for a second RSV season [abstract no. 993]. Pediatr Res 1999; 45: 170ACrossRefGoogle Scholar
  16. 16.
    Prevention of respiratory syncytial viras infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102(5): 1211–6Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations